HSBC Holdings’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

HSBC Holdings’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,085	Closed	-$8K	–	3532
2022 Q1	$8K	Sell	11,085 -3,922	-26%	-$4.3K	﹤0.01%	3241
2021 Q4	$35K	Hold	15,007	–	–	﹤0.01%	3218
2021 Q3	$69K	Hold	15,007	–	–	﹤0.01%	2917
2021 Q2	$66K	Buy	15,007 +3	+0%	+$15	﹤0.01%	2876
2021 Q1	$108K	Sell	15,004 -392	-3%	-$3.23K	﹤0.01%	2630
2020 Q4	$118K	Buy	+15,396	New	+$103K	﹤0.01%	2928

Other funds holding LOGC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HSBC Holdings's LOGC Position: Q2 2022 in Review

HSBC Holdings sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2022, closing a stake of 11,085 shares — an estimated $8K sold.

HSBC Holdings first reported a position in LOGC in Q4 2020 and held it in 6 quarters. The position peaked at $118K in Q4 2020. 47 funds tracked by Wall St. Rank hold LOGC as of Q2 2022.

HSBC Holdings reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
HSBC Holdings sold 11,085 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $8K.
HSBC Holdings first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
HSBC Holdings's LogicBio Therapeutics, Inc. Common Stock position peaked at $118K in Q4 2020.
47 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2022.

Based on HSBC Holdings's 13F filing for Q2 2022, filed 11 Aug 2022.